NCR-300 is under clinical development by Nuwacell Biotechnology and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NCR-300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NCR-300 overview

NCR-300 is under investigation for the treatment of high grade ovarian serous carcinoma, endometrioid carcinoma, primary peritoneal carcinoma, relapse acute myeloid leukemia and fallopian tube carcinoma, myelodysplastic syndrome and unspecified indication. It is administered through intravenous and intraperitoneal routes. The therapeutic candidate comprises of natural killer cells.

Nuwacell Biotechnology overview

Nuwacell Biotechnology focuses on stem cell research and product development. Nuwacell Biotechnology is headquartered in Hefei, Anhui, China.

For a complete picture of NCR-300’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.